Zystektomie beim schlecht differenzierten T1-Harnblasenkarzinom - oft zu früh?

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Aktuelle Urologie

• Publication date

  1998-03-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/s-2008-1065262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The treated natural history of high risk superficial bladder cancer: 15-year outcome.

  1997cited by this paper
• T1-Blasenkarzinom: Indikation zur transurethralen Elektroresektion oder zur primären radikalen Zystektomie?

  1997cited by this paper
• BCG in perspective: advances in the treatment of superficial bladder cancer.

  1995cited by this paper
• [T1 G3 bladder tumors: the respective role of BCG and cystectomy].

  1995cited by this paper
• Experimentelle und klinische Untersuchungen zur Biologie des Harnblasenkarzinoms

  1993cited by this paper
• Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival.

  1991cited by this paper
• Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression.

  1989cited by this paper
• Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?

  1987cited by this paper
• Radikale Zystektomie - Oft zu spät?

  1986cited by this paper

• Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial.

  2010cites this paper
• The optimal management of T1G3 bladder cancer

  2008cites this paper
• G3T1 bladder carcinoma

  2008cites this paper
• Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette‐Guérin (Danish 1331 strain)

  2002cites this paper
• Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.

  2000cites this paper